ArticleLeukemia2025

Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities.

Haruya Okamoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.